Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings

Executive Summary

Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.

You may also be interested in...

Bronchitol Gets Final NICE OK, TOBI Podhaler Trumps Colobreathe

Pharmaxis’ Bronchitol became the first cystic fibrosis drug to get a NICE final approval, while Novartis’s TOBI Podhaler was selected ahead of Forest Lab’s Colobreathe for bacterial infection.

Extension Of Eliquis’ Indication Will See It Face Off Against Xarelto And Pradaxa In Europe

Europe’s top drug regulator recommended an additional indication for Bristol-Myers Squibb/ Pfizer’s Eliquis for AF, setting the stage there for a showdown with Bayer/J&J’s Xarelto and Boehringer Ingelheim’s Pradaxa.

European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come

It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts